AP102

AP102 is an investigational, di‑iodinated, disulfide‑bridged octapeptide somatostatin analog that shows high selectivity for somatostatin receptor subtypes 2 and 5 and is being developed primarily for the treatment of acromegaly and neuroendocrine tumors.[1][3][5][13][12] By preferentially activating SSTR2 and SSTR5, AP102 is designed to potently inhibit pituitary growth hormone secretion and reduce hormone hypersecretion from neuroendocrine tumors, with the goal of improving efficacy and potentially minimizing off‑target effects compared with earlier somatostatin analogs.[1][3][13][10][12] The drug has been characterized preclinically and analytically, but its clinical development status and regulatory approvals remain limited to early‑stage and experimental contexts.[3][5][12]

Other names

AP 102AP102AP-102